PT - JOURNAL ARTICLE AU - Jean-Louis Georges AU - Floriane Gilles AU - Hélène Cochet AU - Alisson Bertrand AU - Marie De Tournemire AU - Victorien Monguillon AU - Maeva Pasqualini AU - Alix Prevot AU - Guillaume Roger AU - Joseph Saba AU - Joséphine Soltani AU - Mehrsa Koukabi-Fradelizi AU - Jean-Paul Beressi AU - Cécile Laureana AU - Jean-François Prost AU - Bernard Livarek TI - Positive association of Angiotensin II Receptor Blockers, not Angiotensin-Converting Enzyme Inhibitors, with an increased vulnerability to SARS-CoV-2 infection in patients hospitalized for suspected COVID-19 pneumonia AID - 10.1101/2020.08.30.20182451 DP - 2020 Jan 01 TA - medRxiv PG - 2020.08.30.20182451 4099 - http://medrxiv.org/content/early/2020/09/01/2020.08.30.20182451.short 4100 - http://medrxiv.org/content/early/2020/09/01/2020.08.30.20182451.full AB - Background Angiotensin converting enzyme (ACE) type 2 is the receptor of SARS-CoV-2 for entry into lungs cells. Because ACE-2 may be modulated by ACE inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs), there is concern that patients treated with ACEIs and ARBs are at higher risk for COVID-19 infection.Aim This study sought to analyze the association of COVID-19 with previous treatment with ACEI and ARB.Methods We retrospectively reviewed 684 consecutive patients hospitalized for suspected COVID-19 pneumonia and tested by PCR. Patients were split into 2 groups, whether (group 1, n=484) or not (group 2, n=250) COVID-19 was confirmed. Multivariate adjusted comparisons included a propensity score analysis.Results Age was 63.6±18.7 years, and 302(44%) were female. Hypertension was present in 42.6% and 38.4% patients of group 1 and 2, respectively (P=0.28). A treatment with ARBs (20.7% versus 12.0%, respectively, OR 1.92, 95% confidence interval [1.23-2.98], p=0.004) was more frequent in patients of group 1 than in group 2. No difference was found for treatment with ACEIs (12.7% vs 15.7%, respectively, OR 0.81 [0.52-1.26], p=0.35). Propensity score matched multivariate logistic regression confirmed a significant association between COVID-19 and a previous treatment with ARBs (adjusted OR 2.18 [1.29-3.67], p=0.004). Significant interaction between ARBs and ACEIs for the risk of COVID-19 was observed in patients aged>60, women, and hypertensive patients.Conclusion This study suggests that ACEIs and ARBs are not similarly associated with the COVID-19. In this retrospective series, patients with COVID-19 pneumonia received more frequently a previous treatment with ARBs, than patients without COVID-19.Competing Interest StatementJLG has received consultant or speaker fees from AstraZeneca France, Sanofi-Aventis, Amgen, and Merck Sharpe and Dohme, which are not related to the present work. No conflicts of interest were disclosed for the other authors.Clinical TrialNCT04374695Funding StatementThis study was founded by the Centre Hospitalier de Versailles, Le Chesnay, France. The authors received no specific funding for this work.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by Comite de Protection des personnes Ouest VI (CPP Ouest 6; CPP 1296 HPS3; Number 2020 A01516 33) Written consent of patients was obtainedAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll relevant data are within the manuscript and its Supporting Information files